International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of all issues and individual articles published by the Journal since 1997.

LEARN MORE

Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension

Author(s):

Issue: May/Jun 2018 - Volume 22, Number 3
View All Articles in Issue

Page(s): 263

Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension Page 1

Download in electronic PDF format for $75

Abstract: Erratum for Allen LV Jr. Lansoprazole 3-mg/mL oral suspension. IJPC 2010; 14(3): 246.

Related Keywords: erratum, formulation, lansoprazole

Related Categories: FORMULATIONS, GASTROENTEROLOGY

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension	May/Jun 2018 Pg. 263
Lansoprazole 3-mg/mL Oral Suspension Allen Loyd V Jr	May/Jun 2010 Pg. 246
Lansoprazole 3-mg/mL in Ora-Blend Suspension Allen Loyd V Jr	Sep/Oct 2022 Pg. 429
Lansoprazole 3-mg/mL Oral Suspension	Jan/Feb 2025 Pg. 46
Lansoprazole 3-mg/mL Oral Liquid Allen Loyd V Jr	Jan/Feb 2007 Pg. 74
Basics of Compounding for Cough Allen Loyd V Jr	Nov/Dec 2004 Pg. 462-465
Compounding in the Pharmacy Curriculum: Beyond the Basics Hinkle Amanda R, Newton Gail D	May/Jun 2004 Pg. 181-185
Erratum: Stability of Venlafaxine Immediate-Release Suspensions Allen Loyd V Jr	Mar/Apr 2011 Pg. 175
Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration Trissel Lawrence A, Saenz Christopher, Williams Kimberly Y, Ingram Delshalonda S	Jul/Aug 2001 Pg. 314-319
Erratum: Zur E. Topical Treatment of Primary Focal Hyperhidrosis, Part 2. IJPC 2019; 23(2):94-104.	Jul/Aug 2019 Pg. 351
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Alexander Kenneth S, Thyangarajapuram N	Sep/Oct 2003 Pg. 389-393
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients Schotik Debora	Jan/Feb 2001 Pg. 9-12
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D	May/Jun 2003 Pg. 233-239
Nitazoxanide 20-mg/mL Oral Suspension Allen Loyd V Jr	Sep/Oct 2023 Pg. 420
Pediatric Oral Formulations: A Continual Challenge Hurtado Josephine, Moffett Brady S	Jan/Feb 2007 Pg. 17-19
Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension Allen Loyd V Jr	Jan/Feb 2021 Pg. 43
Restructuring the Art of Health by Pharmacists: Formulation Designs with Oral Vehicles--Teaching Pharmacy Students Benischek Rita	Mar/Apr 2017 Pg. 105-108
Nimodipine 3-mg/mL Oral Solution Allen Loyd V Jr	Sep/Oct 2015 Pg. 407
Erratum: Allen LV Jr. Lidocaine hydrochloride 2%, misoprostol 0.0024%, and phenytoin 2% topical wound powder. IJPC 2004; 8(4): 298 Allen Loyd V Jr	Mar/Apr 2006 Pg. 82
Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations Sidhom Madiha B, Rivera Nadya, Almoazen Hassan, Taft David R, Kirschenbaum Harold L	Sep/Oct 2005 Pg. 402-406
Return to Top